Rafael Holdings, Inc. (RFL)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Rafael Holdings, Inc. (RFL) trades at $1.26 with AI Score 62/100 (Hold). Rafael Holdings, Inc. operates in both the pharmaceutical and real estate sectors. The company is focused on developing cancer therapies and managing commercial real estate assets. Market cap: $46.30M, Sector: Real estate.
Last analyzed: Feb 9, 2026Rafael Holdings, Inc. (RFL) Real Estate Portfolio & Strategy
Rafael Holdings, Inc. offers a unique investment opportunity through its dual focus on promising cancer therapies like CPI-613 (devimistat) and income-generating commercial real estate, creating a diversified portfolio with potential for high growth and stable returns despite its current negative profitability.
Investment Thesis
Investing in Rafael Holdings presents a compelling, albeit speculative, opportunity. The potential success of CPI-613 (devimistat) in Phase III trials for pancreatic cancer and AML could be a significant value driver. While the company currently has a negative P/E ratio of -1.99 and a substantial negative profit margin of -3044.7%, successful drug development could dramatically alter its financial trajectory. The real estate segment provides a stable revenue stream, offsetting some of the risk associated with pharmaceutical development. The company's relatively low beta of 0.60 suggests lower volatility compared to the broader market. Approval and commercialization of devimistat could lead to substantial revenue growth and improved profitability, making it an attractive investment for risk-tolerant investors seeking high potential returns.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.04 billion, indicating a small-cap company with potential for growth.
- Gross margin of 80.0% suggests strong pricing power in its real estate operations, although this is offset by pharmaceutical development costs.
- Beta of 0.60 indicates lower volatility compared to the overall market, potentially offering a more stable investment.
- Lead drug candidate CPI-613 (devimistat) is in Phase III clinical trials, representing a significant potential catalyst for future growth.
- Operates in two segments (Pharmaceuticals and Real Estate), providing diversification and potential revenue streams.
Competitors & Peers
Strengths
- Dual focus on pharmaceuticals and real estate provides diversification.
- Lead drug candidate CPI-613 (devimistat) in Phase III clinical trials.
- Established real estate assets generate consistent revenue.
- Experienced management team in both pharmaceuticals and real estate.
Weaknesses
- Negative profit margin and P/E ratio.
- Reliance on the success of CPI-613 (devimistat).
- Small market capitalization makes it vulnerable to market fluctuations.
- Limited financial resources compared to larger pharmaceutical companies.
Catalysts
- Completion of Phase III clinical trials for CPI-613 (devimistat) in metastatic pancreatic cancer.
- Completion of Phase III clinical trials for CPI-613 (devimistat) in r/r acute myeloid leukemia.
- Potential FDA approval of CPI-613 (devimistat).
- Expansion of real estate portfolio through strategic acquisitions.
- Progress in developing new cancer therapies.
Risks
- Failure of CPI-613 (devimistat) to achieve positive results in clinical trials.
- Delays or rejection by regulatory agencies.
- Competition from other pharmaceutical companies with more advanced or effective therapies.
- Economic downturn impacting the real estate market and rental income.
- High research and development costs associated with pharmaceutical development.
Growth Opportunities
- Successful Completion of Phase III Trials: The successful completion and FDA approval of CPI-613 (devimistat) for the treatment of metastatic pancreatic cancer and r/r acute myeloid leukemia represents a significant growth opportunity. The market for pancreatic cancer treatment is projected to reach billions of dollars, and devimistat could capture a substantial share if approved. Timeline: Anticipated FDA decision within the next 1-2 years following trial completion.
- Expansion of Pharmaceutical Pipeline: Rafael Holdings can expand its pharmaceutical pipeline through strategic acquisitions or in-licensing agreements. Focusing on novel cancer therapies with strong preclinical or early clinical data could diversify its portfolio and reduce reliance on CPI-613. The market for novel cancer therapeutics is constantly growing. Timeline: Ongoing, with potential for new assets to be added within the next 2-3 years.
- Strategic Partnerships: Forming strategic partnerships with larger pharmaceutical companies for the development and commercialization of CPI-613 or other pipeline assets could accelerate their path to market and reduce financial risk. These partnerships can provide access to resources, expertise, and established distribution networks. Timeline: Potential partnerships within the next 1-2 years, contingent on clinical trial progress.
- Real Estate Portfolio Expansion: Expanding its real estate portfolio through acquisitions or development projects could provide a more stable and predictable revenue stream. Focusing on high-demand commercial properties in strategic locations could enhance long-term value. The commercial real estate market is subject to cyclical trends. Timeline: Ongoing, with potential for acquisitions or development projects within the next 2-3 years.
- Exploiting Metabolic Differences in Cancer Cells: Rafael Holdings can further capitalize on its expertise in exploiting the metabolic differences between normal and cancer cells by developing additional therapies that target these vulnerabilities. This approach could lead to the discovery of new drug candidates with broad applications across various cancer types. Timeline: Long-term, with ongoing research and development efforts.
Opportunities
- Successful commercialization of CPI-613 (devimistat).
- Expansion of pharmaceutical pipeline through acquisitions or partnerships.
- Growth of real estate portfolio through strategic investments.
- Increasing demand for innovative cancer therapies.
Threats
- Failure of CPI-613 (devimistat) in clinical trials.
- Regulatory hurdles and delays in drug approval.
- Competition from larger pharmaceutical companies.
- Economic downturn impacting the real estate market.
Competitive Advantages
- Proprietary knowledge and intellectual property related to CPI-613 (devimistat).
- Established real estate assets providing a stable revenue stream.
- Expertise in targeting metabolic vulnerabilities of cancer cells.
- Ongoing Phase III clinical trials create a barrier to entry for competitors.
About RFL
Rafael Holdings, Inc., headquartered in Newark, New Jersey, is a diversified holding company with interests in both the pharmaceutical and real estate sectors. The company's pharmaceutical operations are centered on the development and commercialization of therapies that target the metabolic vulnerabilities of cancer cells. Their lead drug candidate, CPI-613 (devimistat), is currently undergoing Phase III clinical trials for the treatment of metastatic pancreatic cancer and relapsed or refractory acute myeloid leukemia. The real estate segment involves the leasing of a commercial office building and an associated 800-car public garage. Rafael Holdings' strategy is to create value through its pharmaceutical pipeline and real estate holdings. The company aims to address unmet medical needs in oncology while generating stable income from its real estate assets. While the company's history and founding details are not available in the provided data, its current structure reflects a strategic diversification to balance high-risk, high-reward pharmaceutical development with more predictable real estate revenue. This approach allows Rafael Holdings to potentially capitalize on breakthroughs in cancer treatment while maintaining a degree of financial stability.
What They Do
- Develop and commercialize therapies for cancer treatment.
- Focus on exploiting metabolic differences between normal and cancer cells.
- Lease commercial office buildings.
- Manage and operate public garages.
- Conduct Phase III clinical trials for CPI-613 (devimistat).
- Hold interests in clinical and early-stage pharmaceutical companies.
- Manage real estate assets in the United States and Israel.
Business Model
- Generate revenue through leasing commercial real estate.
- Seek to generate revenue through the future sale of pharmaceutical products, contingent on regulatory approval.
- Potentially generate revenue through partnerships and licensing agreements with other pharmaceutical companies.
Industry Context
Rafael Holdings operates within the real estate services and pharmaceutical industries. The real estate services sector is influenced by macroeconomic factors such as interest rates and economic growth. The pharmaceutical industry is characterized by high research and development costs, regulatory hurdles, and intense competition. Rafael Holdings' success depends on navigating these challenges effectively. Its focus on cancer therapies aligns with the growing demand for innovative oncology treatments. The company's real estate holdings provide a stable base in a cyclical industry. Competitors in the real estate space include companies like Armada Hoffler Properties (AHT), while pharmaceutical competitors are numerous and depend on the specific therapeutic area.
Key Customers
- Tenants of commercial office buildings.
- Users of the public parking garage.
- Potentially, patients and healthcare providers, pending drug approval.
- Potential pharmaceutical partners.
Financials
Chart & Info
Rafael Holdings, Inc. (RFL) stock price: $1.26 (+0.00, +0.00%)
Latest News
-
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga · Mar 3, 2026
-
12 Health Care Stocks Moving In Monday's Intraday Session
benzinga · Mar 2, 2026
-
12 Health Care Stocks Moving In Friday's After-Market Session
benzinga · Jan 30, 2026
-
Stocks That Hit 52-Week Highs On Tuesday
· Jul 6, 2021
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for RFL.
Price Targets
Wall Street price target analysis for RFL.
MoonshotScore
What does this score mean?
The MoonshotScore rates RFL's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Latest News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Friday's After-Market Session
Stocks That Hit 52-Week Highs On Tuesday
Common Questions About RFL (Real Estate)
What does Rafael Holdings, Inc. do?
Rafael Holdings, Inc. is a diversified holding company operating in the pharmaceutical and real estate sectors. Its pharmaceutical division focuses on developing and commercializing cancer therapies, with a lead drug candidate, CPI-613 (devimistat), currently in Phase III clinical trials. The real estate division involves the leasing of a commercial office building and an associated parking garage. This dual approach allows Rafael Holdings to pursue high-growth opportunities in pharmaceuticals while maintaining a stable revenue base through its real estate assets.
Is RFL stock worth researching?
RFL stock presents a speculative investment opportunity. While the company currently has negative profitability, the potential success of CPI-613 (devimistat) in Phase III trials could significantly increase its value. The real estate segment provides a degree of stability. Investors should carefully consider the risks associated with pharmaceutical development and the company's small market capitalization. A positive outcome in the clinical trials could lead to substantial returns, but failure could negatively impact the stock price. The company's beta of 0.60 suggests lower volatility than the market.
What are the main risks for RFL?
The primary risk for Rafael Holdings is the potential failure of CPI-613 (devimistat) in clinical trials or the inability to obtain regulatory approval. The pharmaceutical industry is inherently risky, with high development costs and uncertain outcomes. Additionally, an economic downturn could negatively impact the real estate market and reduce rental income. Competition from larger pharmaceutical companies with greater resources also poses a threat. The company's small market capitalization makes it vulnerable to market fluctuations and dilutive financing.
What are the key factors to evaluate for RFL?
Rafael Holdings, Inc. (RFL) currently holds an AI score of 62/100, indicating moderate score. Key strength: Dual focus on pharmaceuticals and real estate provides diversification. Primary risk to monitor: Failure of CPI-613 (devimistat) to achieve positive results in clinical trials. This is not financial advice.
How frequently does RFL data refresh on this page?
RFL prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven RFL's recent stock price performance?
Recent price movement in Rafael Holdings, Inc. (RFL) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Dual focus on pharmaceuticals and real estate provides diversification. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider RFL overvalued or undervalued right now?
Determining whether Rafael Holdings, Inc. (RFL) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying RFL?
Before investing in Rafael Holdings, Inc. (RFL), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on the most recent available information. The success of CPI-613 (devimistat) is uncertain and depends on clinical trial outcomes and regulatory approval.